28 Feb Ongoing clinical trial for cancer therapy yielding positive results
Cellectar Biosciences is reporting positive results in an ongoing clinical trial for the company’s lead cancer drug candidate.
Meanwhile, year-end numbers for 2018 show net loss was about the same as the previous year, while research and development costs are down by nearly a third.
In a cohort of patients with multiple myeloma, a cancer of the body’s plasma cells, Cellectar’s therapy resulted in a 30 percent overall response rate in 10 patients. That means levels of a certain cancer marker decreased by 30 percent in that group.
Sorry, the comment form is closed at this time.